Journal
CLINICAL RHEUMATOLOGY
Volume 22, Issue 4-5, Pages 329-332Publisher
SPRINGER-VERLAG
DOI: 10.1007/s10067-003-0716-3
Keywords
chronic myelogenous leukemia (CML); protein tyrosine kinase (PTK); platelet-derived growth factor (PDGF); rheumatoid arthritis (RA); signal transduction inhibitor (STI) 571
Categories
Ask authors/readers for more resources
We report on an 80-year-old man with rheumatoid arthritis (RA) who presented with chronic myelogenous leukemia (CML). Five years after the onset of RA, the CML diagnosis was made. The patient was treated for CML with 300 mg of imatinib mesylate (STI; signal transduction inhibitor 571) for 8 weeks. Laboratory tests showed that the C-reactive protein level, percentage of cells exhibiting the Philadelphia chromosome (Phl), WBC count, and Lansbury index for RA all dropped respectively from 7.5 mg/dl to 1.0 mg/dl, 74.9% to 1%, 25, 100/mul to 9900/mul, and 51% to 14%. Administration of imatinib mesylate is felt to be effective in treating not only CML but also RA in the active stage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available